Topical amlodipine salts for the treatment of anorectal diseases

A method for treating an anorectal disease, comprising topically applying a topical pharmaceutical gel composition to a skin surface of a patient in need thereof, wherein the topical pharmaceutical gel composition comprises:

• about 0.01-1% w/w of an amlodipine salt, as measured as the free base;
• about 5-75% w/w of at least one glycol solvent;
• about 0.1-10% w/w of at least one gelling agent;
• about 5-75% w/w of glycerin;
• about 1-20% w/w of ethanol;
• and
• about 10-40% w/w of water,
• wherein the anorectal disease is chronic anal fissure, and the topical pharmaceutical gel composition is topically applied to an affected area of the skin.

A method for treating an anorectal disease, comprising topically applying a topical pharmaceutical gel composition to a skin surface of a patient in need thereof, wherein the topical pharmaceutical gel composition comprises:

• about 0.01-1% w/w of an amlodipine salt, as measured as the free base;
• about 5-75% w/w of at least one glycol solvent;
• about 0.1-10% w/w of at least one gelling agent;
• about 5-75% w/w of glycerin;
• about 1-20% w/w of ethanol;
• about 10-40% w/w of water;
• and
• a local anesthetic.

A method for treating an anorectal disease, comprising topically applying a topical pharmaceutical gel composition to a skin surface of a patient in need thereof, wherein the topical pharmaceutical gel composition comprises:

• about 0.01-1% w/w of an amlodipine salt, as measured as the free base;
• about 5-75% w/w of at least one glycol solvent;
• about 0.1-10% w/w of at least one gelling agent;
• about 5-75% w/w of glycerin;
• about 1-20% w/w of ethanol;
• about 10-40% w/w of water;
• and
• an anti-inflammatory agent,
• wherein the anti-inflammatory agent is a COX-1 or COX-2 inhibitor, or a mixture thereof.